Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. [electronic resource]
Producer: 20090514Description: 30-9 p. digitalISSN:- 1755-3245
- Administration, Oral
- Animals
- Blood Pressure -- drug effects
- Cyclic GMP -- blood
- Cyclic Nucleotide Phosphodiesterases, Type 5 -- metabolism
- Disease Models, Animal
- Fibrillar Collagens -- metabolism
- Fibrosis
- Hemodynamics -- drug effects
- Hypertension, Pulmonary -- chemically induced
- Hypertrophy, Right Ventricular -- enzymology
- Male
- Monocrotaline
- Myocardium -- enzymology
- Natriuretic Peptides -- metabolism
- Osteopontin -- metabolism
- Phosphodiesterase 5 Inhibitors
- Phosphodiesterase Inhibitors -- administration & dosage
- Piperazines -- administration & dosage
- Pulmonary Artery -- surgery
- Purines -- administration & dosage
- RNA, Messenger -- metabolism
- Rats
- Rats, Sprague-Dawley
- Rats, Wistar
- Sildenafil Citrate
- Stroke Volume -- drug effects
- Sulfones -- administration & dosage
- Time Factors
- Tissue Inhibitor of Metalloproteinase-1 -- metabolism
- Ventricular Pressure -- drug effects
- Ventricular Remodeling -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.